敌手
增食欲素
食欲素受体
对抗
药理学
清醒
睡眠(系统调用)
化学
神经科学
医学
受体
神经肽
内科学
心理学
脑电图
计算机科学
操作系统
作者
David B. Whitman,Christopher D. Cox,Michael J. Breslin,Karen M. Brashear,John D. Schreier,Michael J. Bogusky,Rodney A. Bednar,Wei Lemaire,Joseph G. Bruno,George D. Hartman,Duane R. Reiss,C. Meacham Harrell,Richard L. Kraus,Yuxing Li,Susan L. Garson,Scott M. Doran,Thomayant Prueksaritanont,Chunze Li,Christopher J. Winrow,Kenneth S. Koblan
出处
期刊:ChemMedChem
[Wiley]
日期:2009-05-05
卷期号:4 (7): 1069-1074
被引量:74
标识
DOI:10.1002/cmdc.200900069
摘要
Silent Night: Antagonism of the orexin (or hypocretin) system has recently been identified as a novel mechanism for the treatment of insomnia. Herein, we describe discovery of a dual (OX(1)R/OX(2)R) orexin receptor antagonist featuring a 1,4-diazepane central constraint that blocks orexin signaling in vivo. In telemetry-implanted rats, oral administration of this antagonist produced a decrease in wakefulness, while increasing REM and non-REM sleep.
科研通智能强力驱动
Strongly Powered by AbleSci AI